Hansoh Pharmaceutical Group Company Limited

SEHK:3692 Rapport sur les actions

Capitalisation boursière : HK$108.4b

Hansoh Pharmaceutical Group Résultats passés

Passé contrôle des critères 5/6

Hansoh Pharmaceutical Group a connu une croissance annuelle moyenne de ses bénéfices de 9.4%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 5.7% par an. Les revenus ont augmenté de en hausse à un taux moyen de 5.5% par an. Le rendement des capitaux propres de Hansoh Pharmaceutical Group est 16.9% et ses marges nettes sont de 39%.

Informations clés

9.4%

Taux de croissance des bénéfices

7.5%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie5.6%
Taux de croissance des recettes5.5%
Rendement des fonds propres16.9%
Marge nette39.0%
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Nov 21
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Nov 04
Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Aug 28
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

Aug 07
Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Jul 16
If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Jun 24
Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

May 23
Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 01
Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Mar 28
Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

Mar 04
There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Feb 16
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Dec 08
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Oct 12
Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

Sep 14
Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jul 10
Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Jun 11
These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jan 23
Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Dec 01
Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Oct 19
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Aug 28
Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Jun 09
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

May 19
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?

Apr 22
Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued

Feb 06
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued

Ventilation des recettes et des dépenses

Comment Hansoh Pharmaceutical Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

SEHK:3692 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2412,0984,7144,3162,364
31 Mar 2411,1013,9964,2782,231
31 Dec 2310,1043,2784,2412,097
30 Sep 239,7822,9264,2071,990
30 Jun 239,4592,5754,1721,884
31 Mar 239,4212,5794,1601,789
31 Dec 229,3822,5844,1481,693
30 Sep 229,6752,6524,2661,771
30 Jun 229,9682,7204,3851,849
31 Mar 229,9522,7174,3781,823
31 Dec 219,9352,7134,3711,797
30 Sep 219,5242,6754,1991,630
30 Jun 219,1122,6384,0271,463
31 Mar 218,9012,6033,9451,358
31 Dec 208,6902,5693,8621,252
30 Sep 208,3772,5263,7511,146
30 Jun 208,0632,4833,6411,039
31 Mar 208,3732,5203,8431,080
31 Dec 198,6832,5574,0441,121
30 Sep 198,6152,3574,1581,099
30 Jun 198,5482,1574,2711,077
31 Mar 198,1352,0304,135979
31 Dec 187,7221,9033,999881
31 Dec 176,1861,5953,318576
31 Dec 165,4331,4762,916403

Des revenus de qualité: 3692 a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de 3692 sont plus élevées que l'année dernière 3692. (39%) sont plus élevées que l'année dernière (27.2%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de 3692 ont augmenté de 9.4% par an au cours des 5 dernières années.

Accélération de la croissance: La croissance des bénéfices de 3692 au cours de l'année écoulée ( 83.1% ) dépasse sa moyenne sur 5 ans ( 9.4% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices 3692 au cours de l'année écoulée ( 83.1% ) a dépassé celle du secteur Pharmaceuticals 6.4%.


Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de 3692 ( 16.9% ) est considéré comme faible.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé